Evidence synthesis · §4
Thymic peptides in infection and immune support — summary of findings
Outcome-by-outcome summary with effect, certainty and the reason for each downgrade.
§4Summary of findings
§4.1Summary of findings
Table 7. Summary of findings for Thymic peptides in infection and immune support.
| Outcome | Participants (studies) | Effect as reported | Certainty | Reason for downgrade |
|---|---|---|---|---|
| CD4 and CD8 countsThe outcome the Institute designates as anchor for this indication. | 361 (5) | Low certainty evidence supports a modest effect of thymosin alpha-1 in chronic viral hepatitis in an era of therapy now superseded, and a… | Low | indirectness, imprecision |
| Discontinuation for adverse eventsReported as a summary-of-findings row rather than in a tolerability annex, following a public submission. | 342 (5) | Reported per contributing trial; see the included-studies table | Low | inconsistency, publication bias |
| Serious adverse eventsEvent counts are low; the estimate is imprecise by construction. | 327 (4) | Reported per contributing trial; see the included-studies table | Very low | indirectness, imprecision, publication bias |
| Any adverse eventAscertained by spontaneous report in the contributing trials. | 311 (4) | Reported per contributing trial; see the included-studies table | Very low | risk of bias, imprecision |
| Response to vaccinationA secondary outcome for this indication. Its hierarchical position within each contributing trial is recorded on that trial's abstract where the Institute holds it. | 189 (4) | Reported as a secondary outcome in a subset of contributing trials | Very low | risk of bias, publication bias |
| Infection incidenceA secondary outcome for this indication. Its hierarchical position within each contributing trial is recorded on that trial's abstract where the Institute holds it. | 235 (4) | Reported as a secondary outcome in a subset of contributing trials | Very low | inconsistency, publication bias |
| Certainty ratings describe confidence in the effect estimate for the stated outcome. They are not recommendations and do not transfer between outcomes. | ||||
§4.2Forest plot
Study estimatePooled estimate
§4.3Certainty assessment for the anchor outcome
Table 8. Reasoning recorded against each certainty domain for the anchor outcome.
| Domain | Rating | Reasoning |
|---|---|---|
| Risk of bias | No concern | No serious concern identified in this domain. |
| Inconsistency | No concern | No serious concern identified in this domain. |
| Indirectness | Serious | An outcome that would answer the question was not measured in any contributing trial. |
| Imprecision | Serious | The event count falls below the optimal information size. |
| Publication bias | No concern | No serious concern identified in this domain. |
| Overall: Low certainty. Confidence in the effect estimate is limited. The true effect may be substantially different from the estimate. | ||
Compound Evidence Institute · CEI-ES-033/4 · https://compoundevidence.com/syntheses/thymic-peptide-immune-evidence/summary-of-findings/ · retrieved 30 July 2026